Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company headquartered in Alpharetta, Georgia, with a portfolio focused on nutrition support and opioid-sparing pain management. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Avanos executes its strategy across its Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments.
Recent news releases highlight financial results, segment performance and portfolio changes. Avanos regularly reports quarterly results, detailing net sales, operating income and segment trends for SNS and PM&R, along with non-GAAP measures such as adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted EBITDA and free cash flow. These earnings updates often discuss demand in life-sustaining enteral feeding and neonate solutions, momentum in radiofrequency ablation (RFA) solutions and changes in surgical pain and recovery product volumes.
News coverage also includes strategic transactions and partnerships. Avanos has announced the divestiture of its Hyaluronic Acid product line, including TriVisc and GenVisc 850, to Channel-Markers Medical, and an agreement for WRS Group to acquire its US Game Ready orthopedic rental business while Avanos continues to manufacture and supply Game Ready systems and accessories under a long-term agreement. On the acquisition side, Avanos has reported the purchase of Nexus Medical, adding TKO anti-reflux needleless connector technology to its Specialty Nutrition Systems business.
In addition, Avanos issues updates on leadership changes, organizational restructuring and investor events, such as webcasts of earnings conference calls and presentations at healthcare conferences. Investors and observers can use this page to review how Avanos communicates its transformation progress, portfolio focus and financial performance over time.
GAME READY, an Avanos Medical (NYSE: AVNS) brand, has announced a partnership with NFL defensive end Nick Bosa of the San Francisco 49ers. As the Official Recovery Partner of Bosa, GAME READY will integrate its cold and compression therapy technology into his training and recovery regimen. This collaboration aims to showcase the brand's commitment to supporting elite performance through advanced recovery solutions.
The partnership includes collaborative content, product promotions, and appearances by Bosa across various media platforms. It highlights the importance of effective recovery for peak athletic performance and reinforces GAME READY's position as a trusted brand among top athletes globally.
Avanos Medical (NYSE: AVNS) reported Q2 2024 financial results, showing positive growth and progress in its transformation objectives. Key highlights include:
- Total net sales from continuing operations were $171.7 million, up 1.4% year-over-year
- Net income from continuing operations was $4.3 million, compared to a $4.3 million loss last year
- Adjusted diluted EPS from continuing operations was $0.34, up from $0.24 in Q2 2023
- Adjusted EBITDA increased to $26.8 million from $22.9 million last year
The company's Digestive Health portfolio led growth, while Pain Management and Recovery showed improvement. Avanos maintains its 2024 outlook, expecting revenue between $685-$705 million and adjusted diluted EPS of $1.30-$1.45 from continuing operations.
Avanos Medical, Inc. (NYSE: AVNS) has announced a webcast conference call to discuss its second quarter 2024 financial results on Wednesday, July 31 at 9 a.m. ET. The company will release its financial results before the market opens on the same day. CEO Joe Woody and CFO Michael Greiner will host the call. Investors can join via phone or webcast through the company's website. A replay will be available for one week after the call.
Avanos Medical is a medical technology company focused on delivering clinically superior medical device solutions. The company is committed to addressing important healthcare needs, including providing nutrition solutions and reducing opioid use in post-surgical recovery.
Avanos Medical has appointed Indrani Franchini as a new independent member of its board of directors. She brings extensive experience from global companies, including roles at Alnylam Pharmaceuticals, Alexion Pharmaceuticals, Hess , and Pfizer. This addition expands the board to six directors, with five being independent and a diverse representation, including three women. Franchini's legal and compliance expertise is expected to aid Avanos in addressing critical healthcare needs and advancing its mission.
Avanos Medical, Inc. has appointed Sig Delgado as Senior Vice President, Integrated Supply Chain. Delgado, with over 20 years of experience in manufacturing and supply chain in the medical device industry, will lead the continuous improvement efforts in the company's global supply chain. His expertise will play a important role in achieving the company's transformation goals and enhancing its existing foundation in this area.
Avanos Medical, Inc. announced their first quarter 2024 financial results, showing positive growth in net sales, income, and earnings per share. The company highlighted progress in their transformation initiative, margin expansion targets, and growth objectives in various portfolios. Despite a decrease in gross margin due to transformation costs, Avanos reported an increase in adjusted EBITDA and operating profit. The company also provided a 2024 outlook with revenue estimates and non-GAAP financial measures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.